MXC launches new CBD nutraceuticals line: taps multi-billion-dollar market
Published 14-MAR-2018 11:29 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Specialist medicinal cannabis company, MGC Pharmaceuticals (ASX:MXC), this week launched MGC Nutraceuticals, a new line of CBD and hemp-enhanced vegan products targeting the high-end dietary supplement market.
This new range immediately expands MXC’s consumer product offering into the multi-billion-dollar dietary supplement market with seven new high-end natural vegan products.
This premium product offering is gluten-free, and based on high-grade phytocannabinoids, which have been grown, extracted and processed under MXC’s strict quality control guidelines, alongside natural vegan proteins and vitamins.
The range also meets the EU’s high standards, with health claims complying with EU legislation.
Promoting inner health and well-being, this range includes seven premium products, comprising four supplements and three food grade products in flavours such as forest fruit, blueberry and vanilla.
All of these products have been formulated for daily use, and to promote normal immune system function, improve stress protection, and maintain muscle and bone structure.
MXC is tapping a fruitful and quickly growing market with this new line. Consider that the global nutraceutical market was valued at around US$383.06 billion in 2016 and is expected to expand to some US$56.38 billion by 2022.
Also noteworthy is that MXC’s expansion into this market leverages its existing capabilities, including IP, manufacturing capabilities and marketing distribution, with minimal additional investment.
To accompany the launch, MXC has released a catalogue featuring the entire MGC Nutraceuticals range, which will be available from the newly created online store (to customers in jurisdictions that permit it).
Of course, it should be noted here that MXC is still in its early stages and anything can happen, so investors should seek professional financial advice if considering this stock for their portfolio.
MXC co-founder and CEO, Roby Zomer, said: “MGC’s Nutraceuticals range taps into the large and growing health supplement market, providing a CBD and hemp protein-based range of products to consumers that believe in the health benefits derived from CBD and hemp.
“Our expansion into this complementary market leverages our existing capabilities... meaning we have been able to develop an entirely new range of products for an entirely new market, with minimal additional investment,” Zomer added.
General Information Only
This material has been prepared by StocksDigital. StocksDigital is an authorised representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
